hnRNP H′/hnRNP H2 Inhibitors

hnRNP H′/hnRNP H2 inhibitors are chemicals that target various biochemical pathways to modulate the protein's functions in RNA binding, splicing, and processing. Some inhibitors, such as Spliceostatin A and Pladienolide B, specifically target the spliceosomal SF3b complex, thereby affecting hnRNP H′/hnRNP H2's role in alternative splicing. Spliceostatin A binds to the SF3b complex and blocks pre-mRNA splicing. Pladienolide B also targets the SF3b complex but impairs its interaction with pre-mRNA, which limits hnRNP H′/hnRNP H2's participation in splicing. Another inhibitor, Meayamycin, acts on SF3b1, a specific component of the spliceosome, leading to defective splicing and hindrance of hnRNP H′/hnRNP H2's functional activity in this process.

In addition to affecting splicing mechanisms, other inhibitors target transcription and translation processes that hnRNP H′/hnRNP H2 interacts with. Digoxin, for example, inhibits the Na+/K+ pump, leading to elevated intracellular calcium levels that disrupt hnRNP H′/hnRNP H2's RNA binding affinity. Emetine and Rocaglamide target protein synthesis; the former inhibits the elongation step while the latter inhibits initiation by targeting eIF4A, limiting the protein's mRNA binding opportunities. DRB inhibits CDK9, affecting RNA Pol II CTD phosphorylation and consequently, hnRNP H′/hnRNP H2's roles in mRNA processing. These inhibitors demonstrate the multi-faceted nature of hnRNP H′/hnRNP H2 and the range of biochemical strategies to modulate its activity.